Sugi Predict

Sugi Predict / Compounds / SCHEMBL724176

SCHEMBL724176

SCHEMBL724176

COc1ccc(S(=O)(=O)n2cc(C(=O)c3ccc(F)cc3)nc2-c2ccc(N(C)C)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA4 P22748 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ MAPT P10636 6/20 0.41
▸ HTT P42858 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ APAF1 O14727 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ POLB P06746 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ TAS2R14 Q9NYV8 1/20 0.38
▸ GBA1 P04062 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725514 0.88 CNR2 (0.41) CA1CA2CA4CA9MAPT
SCHEMBL724744 0.88 GABRA2 (0.44) CA1CA2CA4CA9MAPT
SCHEMBL725790 0.85 TUBB4A (0.43) CA1CA2CA9MAPTALDH1A1
SCHEMBL2494639 0.81 PTGS2 (0.39) CA1CA2CA4CA9HTT
SCHEMBL724132 0.81 GABRA2 (0.46) CA1CA2CA4CA9MAPT
SCHEMBL15151734 0.80 GABRA2 (0.46) CA1CA2CA4CA9MAPT
SCHEMBL723249 0.78 NR1H2 (0.41) CA1CA2CA4CA9MAPT
SCHEMBL723239 0.77 SMN1; SMN2 (0.42) CA1CA2CA4CA9HTT
SCHEMBL724351 0.77 TUBB4A (0.51) CA1CA2CA9
SCHEMBL770420 0.76 SMN1; SMN2 (0.48) MAPTHTTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS VERU INC. (US) 2023-08-24 — — US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 CA1 3550/4885CA2 2153/4885CA4 634/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 CA1 3550/4885CA2 2153/4885CA4 634/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 CA1 3505/4885CA2 2033/4885CA4 3729/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB CA1 2305/4885CA2 1431/4885CA4 953/4885
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS TUBB3, TUBB1, TUBB CA1 2118/4885CA2 942/4885CA4 1273/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 CA1 3550/4885CA2 2153/4885CA4 634/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 CA1 3550/4885CA2 2153/4885CA4 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.